文献速递区域麻醉与超声心胸血管麻醉疼痛医学

脂质体布比卡因肋间神经阻滞在胸廓切开术后的药代动力学观察

An Observational Study of the Pharmacokinetics of Surgeon-Performed Intercostal Nerve Blockade With Liposomal Bupivacaine for Posterior-Lateral Thoracotomy Analgesia.
PubMed 文献 · Anesth Analg · 2020-01-01

这项前瞻性观察研究纳入15例后外侧胸廓切开术成人患者,由外科医生行单次多级肋间注射266 mg脂质体布比卡因,主要评估血药浓度峰值时间(Tmax)。结果显示中位Tmax为24小时(IQR 12小时,CI 19.5-28.5),中位Cmax为0.6 μg/mL(IQR 0.3 μg/mL,CI 0.45-0.74),96小时内血药浓度均低于毒性阈值2 μg/mL,无局麻药全身毒性发生。

要点

  • 脂质体布比卡因肋间阻滞后吸收延迟且个体差异大,Tmax可达48小时。
  • 96小时内血药浓度始终低于2 μg/mL的毒性阈值,未出现局麻药毒性。
  • 48小时时超过50%患者胸壁感觉恢复正常,96小时时所有患者阻滞消退。

核心结论

  • 多级肋间注射脂质体布比卡因后全身吸收显著延迟且变异大,但96小时内血药浓度始终远低于毒性阈值。

研究设计与样本

  • 前瞻性观察研究,计划样本量15例成人,实际纳入15例后外侧胸廓切开术患者。
  • 外科医生单次多级肋间注射266 mg脂质体布比卡因,以注射时刻为0时点。
  • 在5、15、30分钟及1、2、4、8、12、24、48、72、96小时采血测血清布比卡因浓度。

主要发现

  • 中位Tmax为24小时(IQR 12小时,CI 19.5-28.5小时),范围15分钟至48小时。
  • 中位Cmax为0.6 μg/mL(IQR 0.3 μg/mL,CI 0.45-0.74 μg/mL),范围0.3-1.2 μg/mL。
  • 96小时时所有患者血清布比卡因浓度低于0.2 μg/mL(不可测)。
  • 15例患者疼痛评分和补救阿片类药物用量变异显著。
  • 48小时时超过50%患者胸壁感觉恢复正常,96小时时所有患者神经阻滞消退,无局麻药毒性发生。

临床怎么用

  • 肋间注射脂质体布比卡因后需关注延迟吸收,尤其术后24-48小时的血药浓度变化。
  • 96小时内血药浓度低于2 μg/mL提示该给药方式全身毒性风险较低。

局限性

  • 样本量小(15例),为观察性研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intercostal nerve blocks with liposomal bupivacaine are commonly used for thoracic surgery pain management. However, dose scheduling is difficult because the pharmacokinetics of a single-dose intercostal injection of liposomal bupivacaine has never been investigated. The primary aim of this study was to assess the median time to peak plasma concentration (Tmax) following a surgeon-administered, single-dose infiltration of 266 mg of liposomal bupivacaine as a posterior multilevel intercostal nerve block in patients undergoing posterolateral thoracotomy. METHODS: We chose a sample size of 15 adults for this prospective observational study. Intercostal injection of liposomal bupivacaine was considered time 0. Serum samples were taken at the following times: 5, 15, and 30 minutes, and 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours. The presence of sensory blockade, rescue pain medication, and pain level were recorded after the patient was able to answer questions. RESULTS: Forty patients were screened, and 15 patients were enrolled in the study. Median (interquartile range [IQR]) Tmax was 24 (12) hours (confidence interval [CI], 19.5-28.5 hours) with a range of 15 minutes to 48 hours. The median (IQR) peak plasma concentration (Cmax) was 0.6 (0.3) μg/mL (CI, 00.45-0.74 μg/mL) in a range of 0.3-1.2. The serum bupivacaine concentration was undetectable (<0.2 μg/mL) at 96 hours in all patients. There was significant variability in reported pain scores and rescue opioid medication across the 15 patients. More than 50% of patients had return of normal chest wall sensation at 48 hours. All patients had resolution of nerve blockade at 96 hours. No patients developed local anesthetic toxicity. CONCLUSIONS: This study of the pharmacokinetics of liposomal bupivacaine following multilevel intercostal nerve blockade demonstrates significant variability and delay in systemic absorption of the drug. Peak serum concentration occurred at 48 hours or sooner in all patients. The serum bupivacaine concentration always remained well below the described toxicity threshold (2 μg/mL) during the 96-hour study period.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Manson WC, Blank RS, Martin LW, et al. An Observational Study of the Pharmacokinetics of Surgeon-Performed Intercostal Nerve Blockade With Liposomal Bupivacaine for Posterior-Lateral Thoracotomy Analgesia. Anesth Analg. 2020. PMID: 32833710. doi:10.1213/ANE.0000000000005115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。